Gordon K, Papp K, Gooderman M, Thaci D, Foley P, Morita A, Kundu S, Kisa R, Napoli A, Banerjee S. Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial. J of Skin [Internet]. 2019 Nov. 9 [cited 2024 Jul. 23];3:S14. Available from: https://jofskin.org/33014/index.php/skin/article/view/741